

Corporate Governance Report

INTRODUCTION

Oncopeptides is a Swedish public limited liability company with its registered office in Stockholm, Sweden. The company's share has been listed on Nasdaq Stockholm since February 22, 2017 and is traded under the ticker symbol ONCO. In addition to the rules laid down by law or other regulations, Oncopeptides applies the Swedish Corporate Governance Code (the "Code") with no exceptions.

Oncopeptides' corporate governance

The purpose of Oncopeptides' corporate governance is to create a clear allocation of roles and responsibilities among the owners, the Board of Directors and management. Corporate governance, management and control of Oncopeptides are allotted among the general meeting, the Board of Directors, its elected committees and the CEO.

Examples of external regulations that affect corporate governance

- The Swedish Companies Act,
- Regulatory framework for external statements
- Nasdaq Stockholm's Rule Book for Issuers
- Swedish Corporate Governance Code
- Other applicable regulations and recommendations

Examples of internal regulations that are significant to corporate governance

- Articles of Association
- Board of Directors' rules of procedure, including instructions to Board committees
- Instructions for the CEO

- Guidelines for remuneration of senior management
- Code of Conduct
- Financial manual
- IT policy
- Information policy
- Insider policy
- Anti-Corruption Policy

Shareholders and the share

Oncopeptides had 27,334 shareholders at year-end 2021. The total number of shares was 75,291,841. There was only one share class. Each share entitles the holder to one vote at the AGM, and all shares carry equal rights to the company's assets and earnings. At December 31, 2021, HealthCap VI LP and Stiftelsen Industrifonden were the single largest shareholders in Oncopeptides, with a total of 11,322,400 and 7,420,805 shares, respectively, corresponding to 15 percent and 9.9 percent of the votes and capital. No shareholder other than HealthCap VI LP and Stiftelsen Industrifonden has a direct or indirect shareholding that represents at least one-tenth of the voting rights of all shares in the company. Further information about shareholders and the Oncopeptides share is presented under the heading "The share" in the 2021 Annual Report.

General meetings of shareholders

The company's highest decision-making body is the general meeting of shareholders. At the general meeting, shareholders can exercise their influence in the company. The AGM is to be held within

six (6) months of the end of the financial year. The AGM resolves, for example, on the election of the Board of Directors and, where appropriate, the auditors as well as the principles for the appointment of the Nomination Committee, and discharge from liability for the Board of Directors and the CEO for the preceding year. Other issues to be resolved include the adoption of the Annual Report, the appropriation of profit or loss, directors' and auditors' fees, guidelines for remuneration of the CEO and other members of senior management, and incentive programs for co-workers and the Board of Directors.

The Articles of Association state that the AGM is to be held in Stockholm. To attend and vote at general meetings, either in person or through a proxy, shareholders must notify the company of their participation in accordance with the notice convening the meeting. Official notice of general meetings is to be made in the form of an announcement in Post- och Inrikes Tidningar and on the company's website *oncopeptides.com*. Information regarding the notice shall also be advertised in Dagens Industri.

2021 AGM

- The AGM for 2021 was held on May 26, 2021 in Stockholm. At the AGM, approximately 59 percent of the total votes were represented. Attorney Johan Winnerblad was elected as the Chairman of the meeting
- The AGM passed resolutions including the following:
- Per Wold-Olsen, Brian Stuglik, Cecilia Daun Wennborg, Jarl Ulf Jungnelius, Per Samuelsson

and Jennifer Jackson were re-elected as Board members. Per Wold-Olsen was re-elected as Chairman of the Board

- Ernst & Young AB was re-elected as the company's auditor, with Anna Svanberg as auditor in charge
- Remuneration of the Chairman of the Board and Board members elected by the AGM, and the auditor was established
- Adoption of the proposed guidelines for remuneration of senior management
- A resolution was passed on the implementation of performance-based incentive programs for the company's employees and temporary personnel, as well as a resolution on a maximum of 1,487,370 warrants to secure the delivery of the shares
- A resolution was passed on the implementation of a performance-based incentive program for some of the company's Board members where the company can enter into share swap agreements with third parties for the delivery of shares
- The AGM resolved in accordance with the Board's proposals for guidelines for remuneration of members of senior management
- Authorization for the Board of Directors to resolve on new share issues, warrants and/or the issue of convertibles with or without preferential rights for shareholders. The authorization may be exercised on one or more occasions up until the 2021 AGM and the number of shares issued under the authorization may not, after full exercise of the authorization, correspond to a dilution

Corporate Governance Report

of more than 20 percent of the total number of shares outstanding at the Annual General Meeting's resolution on the proposed authorization

- Adoption of the balance sheet and income statement
- Discharge from liability for the Board of Directors and the CEO with regard to the 2020 fiscal year
- A resolution was passed on new Articles of Association, with a change in share capital and the number of shares

The minutes and information from the AGM are available at oncopeptides.com.

2022 AGM

The 2022 AGM will be held on Tuesday, June 28, 2022. For the right to participate and more information, refer to page 71 of Oncopeptides' Annual Report for 2021 or oncopeptides.com.

The minutes of the AGM will be available at oncopeptides.com.

Nomination Committee

The Nomination Committee represents the company's shareholders and is charged with preparing the AGM's resolutions on election and remuneration matters. The Nomination Committee consists of four members, three of whom are to represent the three largest shareholders in the company on the last business day in September 2021, according to statistics from Euroclear Sweden AB. If any of the three largest shareholders chooses to waive their right to appoint a member of the Nomination Committee, this right passes to the shareholder with the next largest shareholding after these shareholders. The fourth person is to be the Chairman of the Board of Directors. The composition of the Nomination Committee is to be publicly announced no later than six months prior to the AGM.

The Nomination Committee observes the rules governing the independence of Board members according to the Swedish Corporate Governance Code.

The Nomination Committee jointly represents approximately 29 percent of the number of shares and votes in the company based on shareholder information at the time of appointment.

Board of Directors

Composition and independence

According to Oncopeptides' Articles of Association, the Board of Directors is to consist of no fewer than three and no more than eight members elected by the AGM for the term until the end of the next AGM. Six Board members were elected at the 2021 AGM.

According to the Swedish Corporate Governance Code, the majority of the Board members elected by the general meeting are to be independent of the company and its management. All Board members are considered independent in relation to the company and its management. Five of the Board members, together with the Chairman of the Board, are also considered independent in relation to major shareholders. Accordingly, Oncopeptides fulfills the Code's requirement with regard to independence.

At the end of the fiscal year, Oncopeptides' Board of Directors comprised six Board members: Chairman of the Board Per Wold-Olsen and Board members Cecilia Daun Wennborg, Jarl Ulf Jungnelius, Per Samuelsson, Brian Stuglik and Jennifer Jackson. For further information about the Board of Directors, see more under the heading "Auditors' Report" or visit oncopeptides.com.

Responsibility and duties of the Board of Directors

After the general meeting, the Board of Directors is the company's highest decision-making body. The Board of Directors is to be responsible for the organization and management of the company's affairs, for example, by establishing targets and strategies, ensuring that procedures and systems

are in place for monitoring set targets, continuously assessing the company's financial position and evaluating its operational management.

Furthermore, the Board of Directors is responsible for ensuring that correct information is given to the company's stakeholders, that the company complies with laws and regulations and that the company prepares and implements internal policies and ethical guidelines. The Board of Directors also appoints the company's CEO and determines his or her salary and other remuneration on the basis of the guidelines adopted by the general meeting.

The Board of Directors adheres to written rules of procedure which are reviewed annually and adopted at the statutory Board meeting. The rules of procedure govern, among other things, the practices and tasks of the Board of Directors, decision-making within the company, the Board's meeting agenda, the Chairman's duties and the allocation of responsibilities between the Board of Directors and the CEO. Instructions for financial reporting and instructions for the CEO are also determined in connection with the statutory Board meeting.

The Board of Directors' work is also carried out based on a yearly meeting schedule that fulfills the Board's need for information. In addition to Board meetings, the Chairman and the CEO maintain an ongoing dialog regarding the management of the company.

The Board of Directors meets according to a predetermined annual schedule and at least five ordinary Board meetings are to be held between each AGM. In addition to these meetings, extra

Representatives

Shareholders

Staffan Lindstrand, Chairman

HealthCap VI L.P.

Patrik Sobocki

Stiftelsen Industrifonden

Ulrik Grönvall

Swedbank Robur fonder

Per Wold-Olsen

Chairman of the Board of Oncopeptides AB

Corporate Governance Report

meetings can be arranged to address matters which cannot be deferred to any of the scheduled meetings.

For 2021, an evaluation of the Board's work was conducted in the form of individual interviews between the Chairman of the Board and the other Board members. The results will be taken into consideration for the Board's work in 2022.

Board of Directors' work and significant events in 2021

The Board met on 21 occasions during the year, four of which were held per capsulam.

The Board of Directors has mainly dealt with and made decisions in matters related to the company's strategic direction, primarily following the withdrawal of Pepaxto in the U.S., the possibility of approval in Europe, organizational changes, and external reporting and cash flow forecasts.

Board committees

The Board of Directors has set up three committees, the Audit Committee, Remuneration Committee, and the Scientific Committee which all work according to procedures established by the Board.

Audit Committee

The Audit Committee's role is primarily to monitor the company's financial position and the effectiveness of the company's internal control and risk management. The committee is to remain informed about the audit of the Annual Report and consolidated financial statements, and to review and monitor the auditor's impartiality and independence. The Audit Committee also assists the Nomination Committee in preparing proposals for resolution on the election and remuneration

of the auditors. The Audit Committee continues to consist of the following members since the AGM on May 26, 2021:

- Cecilia Daun Wennborg (Chairperson)
- Per Samuelsson
- Per Wold-Olsen

The committee was convened ten times in 2021. Oncopeptides' auditors participated in five of these meetings, at which the topics discussed included the auditors' planning of the audit, observations and examination of the company and its financial statements. Other meetings mainly concerned cash flow forecasts and cost savings.

Remuneration Committee

The Remuneration Committee's role is primarily to prepare matters for recommendation to the Board regarding remuneration and other terms of employment for the CEO and CFO and to review with the CEO the plans for remuneration for other members of senior management. The Remuneration Committee also formulates the CEO's bonus plan, and monitors ongoing and completed programs for variable remuneration of the company's management as well as monitors and evaluates the implementation of the guidelines for remuneration of senior management adopted by the AGM. Following the AGM on May 26, 2021, the Remuneration Committee consists of the following members:

- Per Wold-Olsen (Chairman)
- Brian Stuglik
- Per Samuelsson

The Remuneration Committee was convened seven times in 2021. At these meetings, the committee discussed the company's existing remuneration

systems and proposed guidelines for the remuneration of the CEO and members of senior management as well as the aims, terms and conditions of the incentive programs adopted by the AGM on May 26, 2021.

Scientific Committee

The Scientific Committee was established in June 2021.

The role of the scientific committee is to advise on scientific matters. As part of its responsibilities, the committee evaluates research strategies, clinical development plans, regulatory pathways and strategies, and reviews and reports to the board on emerging areas of science.

The scientific committee is comprised of:

- Jennifer Jackson (Chairman)
- Brian Stuglik
- Jarl Ulf Jungnelius

The Scientific Committee was convened on four informal occasions in 2021. At these meetings, the committee discussed the scientific development of the company.

CEO AND MANAGEMENT

The role of the CEO is subordinate to the Board of Directors. The CEO's main task is to carry out the company's ongoing management and the daily activities of the company. The rules of procedure for the Board of Directors and the instructions for the CEO stipulate which matters the Board is to resolve upon, and which matters fall within the CEO's area of responsibility. Furthermore, the CEO is responsible for preparing reports and necessary information for decision-making prior to Board meetings and presenting the material at Board meetings.

Oncopeptides' management team consisted, as per December 31, 2021 of eight individuals. In addition to the CEO, management comprises the company's Chief Financial Officer, Chief Operating Officer, Head of Research & CMC, Global Head of Corporate Communications, General Counsel, Chief Medical Officer and Global Head Medical Affairs. For information on the management team, see more under the heading "Auditor's Report" or oncopeptides.com.

REMUNERATION OF THE BOARD OF DIRECTORS AND MEMBERS OF SENIOR MANAGEMENT

Remuneration of Board members

The AGM on May 26, 2021 resolved that fees to Board members for the period up to and including the end of the 2021 AGM should comprise SEK 687,500 to the Chairman of the Board and SEK 275,000 to each of the other Board members. In addition to fees for regular Board work, it was resolved that each Board member residing in the U.S. should receive an extra fee of SEK 100,000 and that each Board member residing in Europe outside the Nordic region should receive an extra fee of SEK 50,000.

As remuneration for committee work, it was resolved that the Chairman of the Audit Committee would receive SEK 82,500 and other members of the Audit Committee SEK 27,500 each. It was also resolved that the Chairman of the Remuneration Committee would receive SEK 55,000 while the other members of the Remuneration Committee would receive SEK 27,500 each.

The fees determined in 2021 to Board members elected by the AGM are shown in the table on the next page.

Corporate Governance Report

Board member	INDEPENDENT IN RELATION TO			REMUNERATION, SEK THOUSAND ³				ATTENDANCE ¹		
	Function	The company and its management	Major shareholders	Board fees	Audit Committee	Remuneration Committee	Total	Board of Directors ²	Audit Committee	Remuneration Committee ²
Per Wold-Olsen	Chairman	Yes	Yes	704	26	53	783	20/21	10/10	7/7
Jonas Brambeck ⁴	Board member	Yes	No	125	13	13	150	6/6	1/2	4/4
Cecilia Daun-Wennborg	Board member	Yes	Yes	263	79	–	341	21/21	10/10	–
Per Samuelsson	Board member	Yes	No	263	26	26	315	21/21	10/10	7/7
Jarl Ulf Jungnelius	Board member	Yes	Yes	263	–	–	263	21/21	–	–
Brian Stuglik	Board member	Yes	Yes	358	–	14	371	21/21	–	3/3
Jennifer Jackson	Board member	Yes	Yes	358	–	–	358	21/21	–	–
Total				2,331	144	105	2,580			

1) Figures in table show the total number of meetings attended/total number of meetings.

2) Excluding per capsulam meetings.

3) Fee set by the AGM, excluding social security contributions for the May 2021 to May 2022 fiscal year.

4) Jonas Brambeck declined re-election in connection with the 2021 AGM.

Corporate Governance Report

Guidelines for remuneration of senior management

Issues pertaining to remuneration of members of senior management are addressed by the Board's Remuneration Committee. The Board decides on the CEO's remuneration based on the proposal presented by the Remuneration Committee. Remuneration and terms for members of senior management are to be based on market conditions and consist of a balanced mix of fixed salary, variable remuneration, pension benefits and terms upon termination. For the 2021 fiscal year, the CEO and other members of senior management received salary and other remuneration as set out in Note 10 in the Annual Report.

Guidelines were adopted at the 2021 AGM valid for the period up to the closing of the 2022 AGM. The main points were as follows:

Oncopeptides' starting point is that salary and other terms and conditions should always enable Oncopeptides to attract and retain qualified members of senior management at a reasonable cost for the company. Remuneration of members of senior management is to be decided in accordance with Oncopeptides' remuneration policy, which is adopted annually by the Board and comprises a supplement to the guidelines.

Remuneration of members of senior management consists of a fixed salary, variable remuneration, pension and other benefits. To avoid unnecessary risks being taken by members of Oncopeptides' senior management, there should be a fundamental balance between fixed and variable remuneration. Furthermore, Oncopeptides' AGM may, if so ordered, offer long-term incentive programs, such as share or share price-related incentive programs.

Each member of senior management is to be offered a market-level fixed salary based on the degree of difficulty of the work and the individual's responsibilities, experience and performance. In addition, each member of senior management may, from time to time, be offered variable remuneration (bonus) to be paid in cash. The variable cash remuneration shall be linked to predetermined and measurable criteria which can be financial or non-financial. They may be individualized, quantitative or qualitative objectives. The criteria shall be designed so as to contribute to the company's business strategy and long-term interests, including its sustainability, by for example being clearly linked to the business strategy or promote the executive's long-term development.

These guidelines enable the company to offer the members of senior management a competitive total remuneration. Variable cash remuneration covered by these guidelines shall aim at promoting the company's business strategy and long-term interests, including its sustainability. Long-term share-based incentive programs have been implemented in the company. Such programs have been resolved by the general meeting and are therefore excluded from these guidelines. The programs include senior management, Board members, founders and other personnel, and are reported under Note 27, Share-based remuneration on pages 57-60 of the 2021 Annual Report.

The performance criteria for variable remuneration of the CEO were chosen to help realize the company's strategy and to encourage ownership aligned with the company's long-term interests. The strategic goals together with the short- and

long-term business priorities for 2021 were considered when selecting the performance criteria. Moreover, the non-financial performance criteria contribute to sustainability adaptation and to the company's values.

The fixed salary during the notice period, together with severance pay, may not exceed 24 months' fixed salary.

The Board of Directors is entitled to deviate from the guidelines in individual cases should there be special reasons for doing so. Before every AGM, the Board of Directors is to consider whether or not additional share or share price-related incentive programs should be proposed to the general meeting.

It is the general meeting that resolves upon such incentive programs. Incentive programs are to promote long-term value growth and align the interests of participating members of senior management with those of the shareholders.

New share issues and transfers of securities resolved upon by the general meeting in accordance with the rules of Chapter 16 of the Swedish Companies Act are not covered by the guidelines insofar as the AGM has taken, or will take, such decisions.

Variable remuneration of members of senior management

No variable remuneration was paid to members of senior management for 2021.

As the company voluntarily withdrew Pepaxto from the U.S. market, it decided to close down its commercial operations in the U.S. and Europe and to restructure the Parent Company. CEO Marty J

Duvall left the company on November 15 without variable remuneration/bonus becoming payable. No new targets for variable remuneration were set for Jakob Lindberg when he took office as CEO in November 2021.

The outcome of the 2021 performance criteria has therefore not been calculated or valued. For more information, see Note 10.

SHARE-BASED INCENTIVE PROGRAMS

Oncopeptides currently has nine active programs encompassing management, certain Board members, founders and employees. "Employee Option Program 2016/2023" was introduced in 2016. At the 2018 AGM, two incentive programs were established: "Co-worker LTIP 2018" and "Board LTIP 2018". At an EGM in December 2018, "Board LTIP 2018.2" was implemented, and at the 2019 AGM, it was resolved that two new incentive programs were to be introduced: "Co-worker LTIP 2019" and "Board LTIP 2019". At the 2020 AGM, a resolution was passed to introduce the program "Board LTIP 2020", and at the EGM in December 2020, it was resolved to introduce the program "US Co-worker LTIP 2020," which after the closure in the U.S. is no longer active. At the general meeting in May 2021, it was resolved to introduce the programs "Board LTIP 2021" and "Co-worker LTIP 2021". All options have been transferred at market prices according to independently determined valuation and are subject to customary conversion terms. A brief description of the active programs follows below. See Note 27 in the 2021 Annual Report for further information on the incentive programs.

Corporate Governance Report

Employee Option Program 2016/2023

Employee options were allotted free of charge to participants. Allotted employee options are vested gradually over a four-year period calculated from the starting date (aside from 60 options in the series that vested and were allotted over a period of 12 months). Vesting requires that the holder remain employed by the company and that the employment is not terminated as per the day of vesting of each employee option. Each vested option entitles the holder to subscribe for 900 new shares in the company up to and including November 30, 2023 at the latest.

Co-worker LTIP 2017

The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to, Oncopeptides. Once the options are vested, they can be exercised within a four-year period.

Each vested option entitles the holder to acquire one share in the company at a predetermined price. The price per share is to be equivalent to the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the five trading days preceding the allotment date.

Co-worker LTIP 2019

The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary

exceptions, the participants remain as employees of, or continue to provide services to, Oncopeptides. Once the options are vested, they can be exercised within a four-year period. Each vested option entitles the holder to acquire one share in the company at a predetermined price. The price per share is to be equivalent to the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the five trading days preceding the allotment date.

Co-worker LTIP 2021

The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to, Oncopeptides. Once the options are vested, they can be exercised within a four-year period. Each vested option entitles the holder to acquire one share in the company at a predetermined price. The price per share is to be equivalent to the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the five trading days preceding the allotment date.

Board LTIP 2018.2

The share awards were allotted to participants free of charge. Share awards are vested over a three-year period, with one-third per 12-month period after the allotment date. The share awards are also subject to performance-based vesting, based on the performance of Oncopeptides' share price during the period from the allotment date

up to and including the final vesting date. The share price's performance will be measured as the volume-weighted average price of the company's share 10 trading days immediately after the allotment date and 10 trading days immediately before the final vesting date. If Oncopeptides' share price has then increased by over 60 percent, 100 percent of the share awards will be vested, and if the share price has increased by 20 percent, 33 percent of the share awards will be vested. In the event of an increase in the share price by 20 to 60 percent, the share awards will be vested in a linear manner. If the share price increases by less than 20 percent, there will be no vesting. Each time-based and performance-based vested share award entitles the holder to obtain one share in Oncopeptides free of charge.

Vested share awards can be exercised at the earliest on the day after the last vesting date.

Board LTIP 2019

The share awards were allotted to participants free of charge. Share awards are vested over approximately three years until either the 2022 AGM or June 1, 2022 (whichever occurs first) with one-third per year during the period from one AGM to the date immediately before the next AGM or the final vesting date. The share awards are also subject to performance-based vesting, based on the performance of Oncopeptides' share price during the period from the allotment date up to and including the day before the final vesting date. The share price's performance will be measured as the volume-weighted average price of the company's share 10 trading days immediately after the allot-

ment date and 10 trading days immediately before the final vesting date. If Oncopeptides' share price has then increased by over 60 percent, 100 percent of the share awards will be vested, and if the share price has increased by 20 percent, 33 percent of the share awards will be vested. In the event of an increase in the share price by 20 to 60 percent, the share awards will be vested in a linear manner. If the share price increases by less than 20 percent, there will be no vesting. Each time-based and performance-based vested share award entitles the holder to obtain one share in Oncopeptides free of charge.

Vested share awards are automatically exercised the day after the vesting period.

Board LTIP 2020

The program is share based and is aimed at the main shareholder-independent Board members of the company. In total, the program comprises a maximum of 37,150 share awards and the number of share awards to be allotted to each participant shall correspond to a certain sum (SEK 1,350,000 to the Chairman of the Board of Directors and SEK 540,000 to each of the other main shareholder-independent Board members) divided by the volume-weighted average price of the company's share on Nasdaq Stockholm during 10 trading days prior to the allotment date. The share awards are subject to performance-based vesting based on the development of the share price for the company's share during the period from the date of allotment until the earlier of (i) the 2023 AGM or (ii) June 1, 2023. Each vested share award entitles the holder to obtain one share in the company

Corporate Governance Report

free of charge, provided that the holder is still a member of the Board of the company at the relevant vesting dates. In addition, it was resolved in accordance with the Nomination Committee's proposal to issue a maximum of 37,150 warrants to ensure the delivery of shares under Board LTIP 2020.

Board LTIP 2021

The program is share based and is aimed at the main shareholder-independent Board members of the company. In total, the program comprises a maximum of 35,000 share awards and the number of share awards to be allotted to each participant shall correspond to a certain sum (SEK 1,500,000 to the Chairman of the Board of Directors and SEK 600,000 to each of the other main shareholder-independent Board members) divided by the volume-weighted average price of the company's share on Nasdaq Stockholm during 10 trading days prior to the allotment date. The share awards are subject to performance-based vesting based on the development of the share price for the company's share during the period from the date of allotment until the earlier of (i) 2024 AGM or (ii) June 1, 2024. Each vested share award entitles the holder to obtain one share in the company free of charge, provided that the holder is still a member of the Board of the company at the relevant vesting dates. For the issued share rights, it was decided not to issue any warrants.

The table is a summary of the total number of shares to which allotted employee options and share awards may entitle the holder at December 31, 2021.

NUMBER OF SHARES TO WHICH GRANTED INSTRUMENTS MAY ENTITLE THE HOLDER TO AS OF DECEMBER 31, 2021

- Employee Option Program 2016/2023	65,700
- Co-worker LTIP 2017	1,228,582
- Co-worker LTIP 2018	185,191
- Co-worker LTIP 2019	672,903

Total number of shares to which granted employee options may entitle the holder	2,152,376
--	------------------

- Board LTIP 2018.2	2,170
- Board LTIP 2019	23,491
- Board LTIP 2020	26,931
- Board LTIP 2021	35,000
- Co-worker LTIP 2021	14,489

Total number of shares to which allotted share awards may entitle the holder	102,081
---	----------------

Total number of shares to which granted employee options and share awards may entitle the holder	2,254,457
---	------------------

Dilution

To ensure the delivery of shares to participants in the company's incentive programs as well as to cover social security contributions when options, share awards and employee options are exercised, the Parent Company has issued warrants to its subsidiary Oncoceptides Incentive AB, which

entitle holders to subscribe for a total of 2,219,457 shares in the Parent Company.

The full utilization of granted options and share awards as of December 31, 2021, corresponding to 2,254,457 shares, would result in a dilution of 2.9 percent. The full utilization of all resolved options corresponding to a total of 4,397,484 shares (including unallotted employee options and performance shares as well as warrants intended for hedging of social security contributions) would result in a dilution of 5.5 percent.

EXTERNAL AUDITOR

Oncoceptides' auditor is the accounting firm Ernst & Young AB (EY), with authorized public accountant Anna Svanberg as auditor in charge. At the 2021 AGM, EY was re-elected as the auditor for Oncoceptides.

The auditor performs a review engagement of the quarterly report for the third quarter, and audits the annual and consolidated financial statements. The auditor also comments on whether this Corporate Governance Report has been prepared and whether certain information herein is consistent with the annual and consolidated financial statements. The auditor reports on the results of its audit of the Annual Report and consolidated financial statements and review of the Corporate Governance Report via the Auditor's Report as well as a separate opinion on the compliance with guidelines for remuneration of senior management, which the auditor submits to the AGM. In addition, the auditor issues detailed statements on the audits performed to the Audit Committee two times per year as well as to

the Board in its entirety once per year. The fees invoiced by the auditor in the last two fiscal years are disclosed in Note 8 of the 2021 Annual Report.

INTERNAL CONTROL AND RISK MANAGEMENT

The Board of Directors' responsibility for internal control is governed by the Swedish Companies Act and the Swedish Corporate Governance Code. Internal control primarily consists of the following five components: control environment, risk assessment, control activities, information and communication, and monitoring.

Among other tasks, the Board is responsible for ensuring that Oncoceptides has sufficient internal control and formalized procedures to ensure that established principles for financial reporting and internal control are adhered to and that there are appropriate systems in place to monitor and control the company's operations and the risks associated with the company and its operations.

The overall purpose of the internal control is to ensure that the company's operating strategies and targets are monitored and that the owners' investments are protected, to a reasonable degree. Furthermore, the internal control is to ensure, with reasonable certainty, that the external financial reporting is reliable and prepared in accordance with generally accepted accounting principles, that applicable laws and regulations are followed, and that the requirements imposed on listed companies are complied with.

In addition to the aforementioned internal control, there is also an internal, business-specific control of data as regards research and development as well as quality control including system-

Corporate Governance Report

atic monitoring and evaluation of the company's development and manufacturing operations and the company's products.

Control environment

In order to create and maintain a functioning control environment, the Board has adopted a number of policies and steering documents governing financial reporting. These documents primarily comprise the rules of procedure for the Board of Directors, instructions for the CEO and instructions for financial reporting. The Board has also adopted special authorization procedures and a financial policy. The company also has a financial manual which contains principles, guidelines and process descriptions for accounting and financial reporting.

Furthermore, the Audit Committee's main task is to monitor the company's financial position and the effectiveness of the company's internal control, internal audit and risk management, to remain informed about the audit of the Annual Report and consolidated financial statements, and to review and monitor the auditor's impartiality and independence. Responsibility for the ongoing work of the internal control over financial reporting has been delegated to the company's CEO. The CEO regularly reports to the Board of Directors in accordance with the established instructions for the CEO and the instructions for financial reporting. The Board also receives reports from the company's auditor.

Risk assessment

Risk assessment includes identifying risks that may arise if the basic requirements for the financial reporting of the company are not met. Oncopeptides' management team has, in a specific risk assess-

ment document, identified and evaluated the risks that arise in the company's operations, and has assessed how these risks can be managed. Within the Board of Directors, the Audit Committee is primarily responsible for continuously assessing the company's risk situation as related to the company's financial reporting. The Board also conducts an annual review of risks.

Control activities

Control activities limit identified risks and ensure accurate and reliable financial reporting. The Board of Directors is responsible for the internal control and monitoring of the company's management. This is done through both internal and external control activities, and through examination and monitoring of the company's steering documents related to risk management. The effectiveness of the control activities is assessed annually and the results from these assessments are reported to the Board of Directors and the Audit Committee. In agreements with sub-suppliers, the company has secured the right to audit each respective sub-supplier's fulfillment of relevant services, including quality aspects.

Information and communication

The company has information and communication channels to promote the accuracy of the financial reporting and to facilitate reporting and feedback from the operations to the Board and senior management, for example, by making corporate governance documents, such as internal policies, guidelines and instructions regarding the financial reporting, available to the co-workers concerned and ensuring the co-workers are familiar with

them. The Board of Directors has also adopted an information policy governing Oncopeptides' disclosure of information.

Monitoring, evaluation and reporting

Compliance with and effectiveness of the internal controls are constantly monitored. The CEO ensures that the Board of Directors continuously receives reports on the development of the company's activities, including the development of the company's earnings and financial position, as well as information on important events, such as research results and important contracts. The CEO reports on these matters at each Board meeting. The company's compliance with all relevant steering documents and guidelines is assessed annually. The results from these assessments are compiled by the company's CFO and then reported to the Board of Directors and the Audit Committee.

The Board deems that the internal controls are effective in all material respects and, on this basis, has determined that there is no need to establish a special internal-audit function.

EXTERNAL AUDIT

The company's auditor is appointed by the AGM for the period until the end of the next AGM. The auditor examines the Annual Report and accounts as well as the Board of Directors' and the CEO's fulfillment of their fiduciary duties and responsibilities. Following each fiscal year, the auditor submits an Auditor's Report to the general meeting. Each year, the company's auditor reports his observations from the audit and his assessment of the company's internal control to the Board of Directors.

